Outcome of Different IOLs in Patients With and Without Uveitis

Sponsor
Vastra Gotaland Region (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02975895
Collaborator
(none)
300
1
2
71
4.2

Study Details

Study Description

Brief Summary

Cataract, is a clouding of the lens in the eye gradually leading to reduction of the visual acuity. In most cases it can be managed with surgery, removing the own lens and replacing it with an artificial lens, intraocular lens (IOL). These lenses are made in different materials with different properties.

Uveitis refers to an inflammation in the iris, ciliary body and choroid. Patients with this disease have an increased risk of developing cataract due to the inflammation itself and treatment with steroids. They also have an increased risk of complications during surgery and postoperatively. In this group the selection of IOL might be of greater importance.

The aim of this prospective randomized controlled study is to compare the outcome of hydrophobic and hydrophilic intraocular lenses in patients with and without uveitis

Condition or Disease Intervention/Treatment Phase
  • Device: Hydrophobic IOL: Vivinex (HOYA)
  • Device: Hydrophilic IOL: INCISE (Bausch+Lomb)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Outcome With Hydrophobic and Hydrophilic Intraocular Lens in Patients With and Without Uveitis
Actual Study Start Date :
Dec 30, 2016
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Hydrophobic IOL: Vivinex (HOYA)

Intraocular lens with hydrophobic properties: Vivinex (HOYA).

Device: Hydrophobic IOL: Vivinex (HOYA)
Patients requiring cataract surgery will be randomized to one of the two types of IOLs.

Other: Hydrophilic IOL: INCISE (Bausch+Lomb)

Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).

Device: Hydrophilic IOL: INCISE (Bausch+Lomb)
Patients requiring cataract surgery will be randomized to one of the two types of IOLs.

Outcome Measures

Primary Outcome Measures

  1. Change in inflammatory response [Preoperatively and at seven occasions within two years postoperatively]

Secondary Outcome Measures

  1. Evaluation of posterior capsule opacification after six months [Six months (plus or minus 30 days) postoperatively]

  2. Evaluation of posterior capsule opacification after one year [One year (plus or minus 30 days) postoperatively]

  3. Evaluation of posterior capsule opacification after two years [Two years (plus or minus 2 months) postoperatively]

  4. Change in best corrected visual acuity assessed in decimal using Snellen charts [Preoperatively and at six occasions within two years postoperatively]

  5. Complications [Preoperatively and at seven occasions within two years postoperatively]

    Postoperative glaucoma or cystoid macular edema

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Cataract requiring surgery

  • Ability to understand and sign consent form

Exclusion Criteria:
  • Extensive corneal scarring

  • Other eye surgery less than 3 months before inclusion

  • Unregulated glaucoma

  • Active uveitis (increased inflammation and treatment less than 3 months before inclusion)

  • Intraoperative complications (capsular tear or vitreous loss)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vastra Gotaland Region, Sahlgrenska University Hospital, Department of Ophthalmology Mölndal Sweden

Sponsors and Collaborators

  • Vastra Gotaland Region

Investigators

  • Principal Investigator: Madeleine Zetterberg, MD, PhD, Västra Götalands regionen, Sahlgrenska University Hospital, Department of Ophthalmology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Vastra Gotaland Region
ClinicalTrials.gov Identifier:
NCT02975895
Other Study ID Numbers:
  • 031-16
First Posted:
Nov 29, 2016
Last Update Posted:
Apr 27, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 27, 2022